William Grossman, Interim Chief Medical Officer at enGene Therapeutics, bought ENGN on Sep 22, 2026
Data as of Oct 16
▲ BUY$10.1K5,102 shares at $1.97William Grossman Interim Chief Medical OfficerENGN enGene Therapeutics Inc.
- Traded
- Sep 22, 2026
- Disclosed
- Sep 24, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ENGN since disclosure
−13.0%
Similar stocks (XLV) since disclosure
+4.0%
XLV — its sector index fund
Change in closing price from Sep 24, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.